Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer

Jacot, William; Jl, Pujol; Boher, Jean-Marie; Lamy, Pierre‐Jean

doi:10.1038/sj.bjc.6601987

Cited by 17 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore neuron specific enolase (NSE), squamous cancer cell antigen (SCC), cancer antigen 125 (CA 125) and HER2neu have been described [22,32,39,44,45,[54][55][56]72,74,82]. Studies mainly are retrospective observations and include 60 to more than 2000 patients which is critical in several cases with respect to the number of parameters investigated, the number of endpoint events observed, and the subgroup analyses performed.…”

Section: All Tumor Stagesmentioning

confidence: 99%

Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer

Holdenrieder

Nagel

Stieber

2010

CBM

View full text Add to dashboard Cite

Prognostic information on the course of cancer disease is highly relevant for the accurate decision of the most effective treatment strategy for an individual patient. In early stage disease, the application of adjuvant chemo- or radiotherapy after surgery depends on the risk of the patient to early suffer from tumor recurrence. In advanced stage disease, risk stratification of the patients influences the choice of more aggressive or mild therapy alternatives. Besides tumor related parameters like tumor stage and individual factors, additional information by biomarkers is needed to better characterize patients prognosis in both situations. Although there are plenty of studies dealing on the prognostic relevance of diverse biomarkers in non-small cell lung cancer (NSCLC), the results are quite heterogeneous and sometimes conflicting. Reasons for this situation may be found in the design, the performance, the evaluation and the quality of result reporting of the studies. In this review, we focus on the prerequisites of informative prognostic trials, spot on the general shortcomings of studies published so far, and summarize the results of the prognostic studies available for early and advanced stages of NSCLC.

show abstract

Section: All Tumor Stagesmentioning

confidence: 99%

Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer

Holdenrieder

Nagel

Stieber

2010

CBM

View full text Add to dashboard Cite

show abstract

“…Five articles 22-26 originated from investigative groups already represented. In three articles [27][28][29] EGFR protein was measured in serum. One article 30 compared a combined EGFR overexpression or underexpression group with a medium expression group.…”

Section: Collection Of Published Studiesmentioning

confidence: 99%

Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

Nakamura

Kawasaki²,

Taguchi³

et al. 2006

Thorax

117

View full text Add to dashboard Cite

Background: It is thought that overexpression of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) might compromise patient survival, presumably by promoting tumour growth by an autocrine mechanism. However, conflicting results have been reported from various laboratories, and the clinical importance of EGFR overexpression remains unsettled. Methods: A meta-analysis of previous studies was performed to quantitatively review the effects of EGFR overexpression on survival in patients with NSCLC using a DerSimonian-Laird random effects model. Eighteen studies including 2972 patients were subjected to final analysis. Results: Overall, positivity for EGFR overexpression differed between histological types: 39% in adenocarcinomas, 58% in squamous cell carcinomas, 38% in large cell carcinomas, and 32% in cancers in a miscellaneous category (p,0.0001). The combined hazard ratio (HR) was 1.14 (95% CI 0.97 to 1.34; p = 0.103), indicating that EGFR overexpression has no significant impact on survival. When only the 15 immunohistochemistry based studies were considered, the combined HR was 1.08 (95% CI 0.92 to 1.28; p = 0.356), again suggesting that EGFR overexpression has no impact on survival. Heterogeneity testing indicated that there was heterogeneity between studies but publication bias was absent, which suggests that the summary statistics obtained may approximate the actual average. Conclusions: EGFR overexpression was not associated with poorer survival in patients with NSCLC. Specific mutations of the EGFR gene will need further study in terms of survival implications.

show abstract

“…[68,69] However, the current results are quite controversial in either differential diagnosis or treatment effect monitoring. [70] Tissue polypeptide antigen Tissue polypeptide antigen is a traditional tumor marker that detects a mixture of cytokeratin 8, 18, and 19. In pathological studies, cytokeratin and other intermediate products of cell are used to determine tumor differentiation and classification.…”

Section: Cytokeratin 19 Fragmentmentioning

confidence: 99%

Advances in the study of serum tumor markers of lung cancer

Kang

2014

J Can Res Ther

View full text Add to dashboard Cite

Lung cancer is among the most prevalently occurring carcinomas worldwide, and reducing lung cancer mortality depends on early detection, diagnosis, and treatment. Given the rapid development of molecular biology and modern techniques for diagnosis and treatment, the study of serum tumor markers has gained extensive application in early diagnosis, treatment effect monitoring, and prognosis evaluation. Serum tumor markers possess the advantages of easy detection, noninvasive operation, and cost-effectiveness. This article reviews the progress in the study of serum tumor markers of lung cancer.

show abstract

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer

Cited by 17 publications

References 24 publications

Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer

Estimation of prognosis by circulating biomarkers in patients with non-small cell lung cancer

Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

Advances in the study of serum tumor markers of lung cancer

Contact Info

Product

Resources

About